Zacks Research Issues Pessimistic Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research dropped their Q4 2024 EPS estimates for shares of Charles River Laboratories International in a note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.47 for the quarter, down from their prior estimate of $2.50. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2025 earnings at $2.42 EPS, Q2 2025 earnings at $2.44 EPS, Q3 2025 earnings at $2.59 EPS, Q4 2025 earnings at $2.62 EPS, FY2025 earnings at $10.07 EPS, Q3 2026 earnings at $2.88 EPS and FY2026 earnings at $11.70 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.72 EPS.

Other research analysts also recently issued research reports about the stock. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. JPMorgan Chase & Co. downgraded shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $214.38.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $199.23 on Monday. The company has a market capitalization of $10.19 billion, a PE ratio of 24.94, a price-to-earnings-growth ratio of 5.19 and a beta of 1.38. Charles River Laboratories International has a one year low of $176.48 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company’s fifty day moving average price is $194.26 and its 200 day moving average price is $204.39.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock worth $170,615,000 after buying an additional 163,056 shares during the last quarter. 1832 Asset Management L.P. bought a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $33,053,000. Finally, Earnest Partners LLC raised its stake in shares of Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).